Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range from 2 to 10%. The aim of this analysis is to report the frequency, characteristics and outcomes of pts with RT enrolled in trials of the GCLLSG. A total of 2975 pts with advanced CLL were reviewed for incidence of RT. Clinical, laboratory, and genetic data were pooled. Time-to-event data, starting from time of CLL diagnosis, of first-line therapy or of RT diagnosis, were analyzed by Kaplan-Meier methodology. One hundred and three pts developed RT (3%): 95 pts diffuse large B-cell lymphoma (92%) and eight pts Hodgkin lymphoma (8%). Median observation time was 53 months (interquartile range 38.1–69.5). Median OS from initial CLL diagnosis for pts without RT was 167 months vs 71 months for pts with RT (HR 2.64, CI 2.09–3.33). Median OS after diagnosis of RT was 9 months. Forty-seven pts (46%) received CHOP-like regimens for RT treatment. Three pts subsequently underwent allogeneic and two pts autologous stem cell transplantation. Our findings show that within a large cohort of GCLLSG trial participants, 3% of the pts developed RT after receiving first-line chemo- or chemoimmunotherapy. This dataset confirms the ongoing poor prognosis and high mortality associated with RT.

里希特转化（RT）定义为CLL患者（pts）发生侵袭性淋巴瘤。CLL患者中RT的发生率在2％至10％之间。该分析的目的是报告参与GCLLSG试验的RT患者的发生频率，特征和结果。回顾了总共2975例晚期CLL患者的RT发生率。汇总临床，实验室和遗传数据。通过CLP诊断，一线治疗或RT诊断开始的事件时间数据通过Kaplan-Meier方法进行了分析。一百零三名患者发展为放疗（3％）：95分弥散性大B细胞淋巴瘤（92％）和八分霍奇金淋巴瘤（8％）。中位观察时间为53个月（四分位间距38.1–69.5）。无RT的患者从初始CLL诊断开始的中位OS为167个月，而有RT的患者为71个月（HR 2.64，CI 2.09–3.33）。诊断为RT后的OS中位数为9个月。47例（46％）接受了类似CHOP的方案进行RT治疗。随后对3名患者进行了同种异体移植，另2名患者进行了自体干细胞移植。我们的发现表明，在一大批GCLLSG试验参与者中，有3％的患者在接受一线化学或化学免疫治疗后发展为RT。该数据集证实了与RT相关的持续不良预后和高死亡率。我们的发现表明，在一大批GCLLSG试验参与者中，有3％的患者在接受一线化学或化学免疫治疗后发展为RT。该数据集证实了与RT相关的持续不良预后和高死亡率。我们的发现表明，在一大批GCLLSG试验参与者中，有3％的患者在接受一线化学或化学免疫治疗后发展为RT。该数据集证实了与RT相关的持续不良预后和高死亡率。